Elecoglipron

Elecoglipron
Clinical data
Other names	AZD-5004; ECC-5004
Identifiers
	IUPAC name 3-[1-[2-[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyloxan-4-yl]indolizin-3-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one;
CAS Number	3011682-49-5;
PubChem CID	169644648;
IUPHAR/BPS	14376;
UNII	G94JJ74N5Y;
KEGG	D13345;
Chemical and physical data
Formula	C48H46F2N10O5
Molar mass	880.958 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1C2=C(N(N=C2CCN1C(=O)C3=C(N4C=CC(=CC4=C3)[C@H]5CCOC(C5)(C)C)C6(CC6)C7=NOC(=O)N7)C8=CC(=C(C=C8)F)C9CC9)N1C=CN(C1=O)C1=C(C2=C(C=C1)N(N=C2)C)F;
	InChI InChI=InChI=1S/C48H46F2N10O5/c1-26-39-36(53-60(30-7-8-35(49)32(22-30)27-5-6-27)42(39)59-19-18-58(46(59)63)38-10-9-37-34(40(38)50)25-51-55(37)4)12-17-56(26)43(61)33-23-31-21-28(29-13-20-64-47(2,3)24-29)11-16-57(31)41(33)48(14-15-48)44-52-45(62)65-54-44/h7-11,16,18-19,21-23,25-27,29H,5-6,12-15,17,20,24H2,1-4H3,(H,52,54,62)/t26-,29-/m0/s1; Key:JMKBTILBGROESC-WNJJXGMVSA-N;

Elecoglipron is an investigational new drug that is being developed by Eccogene and AstraZeneca for the treatment of obesity, type 2 diabetes mellitus, and liver disorders. It is a glucagon-like peptide-1 receptor agonist. ^[1]^[2]^[3]

References

↑ "Elecoglipron". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Aroda VR, Davies MJ, Maaske J, Millegård M, Juan VL, Aberle J, et al. (June 2026). "Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial". Lancet. 407 (10547). London, England: 2515–2527. doi:10.1016/S0140-6736(26)00802-0. PMID 42259343.
↑ Davies MJ, Aroda VR, Rosenstock J, Capehorn M, Pedersen SD, Morizzo E, et al. (June 2026). "Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial". Lancet. 407 (10547). London, England: 2503–2514. doi:10.1016/S0140-6736(26)00748-8. PMID 42259337.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.